Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp., filed a Form 4 on September 11, 2026, disclosing the vesting of restricted stock units and a related share sale on September 9, 2026, to cover tax withholding obligations.

Key Highlights

  • RSU settlement: 2,462 shares of Class A Common Stock were acquired at $0 upon the vesting and settlement of restricted stock units on September 9, 2026.
  • Tax-cover sale: 1,285 shares were sold at a weighted average price of $84.2179, with individual transaction prices ranging from $84.08 to $84.22 per share.
  • Remaining direct ownership: Following the transactions, Feeley directly holds 41,476 shares of Class A Common Stock.
  • Additional unvested awards: The filing discloses Feeley also holds RSUs representing contingent rights to receive up to 78,864 shares and options to purchase up to 25,906 shares, subject to vesting terms.
  • Sale characterization: According to the filing, the sale "does not represent a discretionary transaction by the Reporting Person" and was executed solely to satisfy tax withholding obligations via a "sell to cover" transaction.

GeneDx CFO Feeley's RSU Vesting Activity and Post-Transaction Holdings

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (NASDAQ:WGS), reported two transactions in Class A Common Stock on September 9, 2026. The first was an acquisition of 2,462 shares coded "M," reflecting the settlement of restricted stock units at no cost to Feeley. Each RSU, the filing states, "represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration."

The second transaction was a sale of 1,285 shares coded "S," executed at a weighted average price of $84.2179. The filing notes the shares were sold across multiple transactions at prices ranging from $84.08 to $84.22 per share. The filing states that Feeley "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."

After both transactions, Feeley directly holds 41,476 shares of Class A Common Stock. The filing also discloses that he holds 2,463 RSUs remaining after the settlement, RSUs covering an additional 78,864 shares in aggregate, and options to purchase up to 25,906 shares, all of which "vest according to their respective terms." The RSU award vests at 6.25% quarterly, with the first tranche having vested on March 9, 2023, and vesting is subject to continued service to the issuer. The Form 4 was signed by Bridget Brown as attorney-in-fact on September 11, 2026.

What Was Disclosed

GeneDx Holdings Corp.'s CFO, Kevin Feeley, disclosed the vesting of 2,462 RSUs and the sale of 1,285 resulting shares at a weighted average of $84.2179 solely to cover tax withholding, leaving him with 41,476 directly held shares as of September 9, 2026.